Results 71 to 80 of about 10,603,245 (304)

Quantification of D-dimer levels in human saliva

, 2013
Background: Plasma D-dimer tests are currently used to exclude deep vein thrombosis and pulmonary embolism. Human saliva has numerous advantages over blood as a diagnostic sample.
Cooper-White, Justin, Punyadeera, Chamindie, Wan, Yunxia, Atherton, John, Dimeski, Goce, Zhang, Xi   +5 more
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Reinfusion of peritoneal fluid elevates the level of plasma D‐dimer in patients with early‐onset ovarian hyperstimulation syndrome

Reproductive Medicine and Biology
Purpose This study aimed to elucidate the factors that affect the dynamics of blood D‐dimer in ovarian hyperstimulation syndrome (OHSS). Methods We retrospectively reviewed medical records from two hospitals and extracted data obtained during assisted ...
Shiori Kumazawa, Kazuki Saito, Nanako Hashido, Rinko Ibi, Tomonori Ishikawa, Akira Wakabayashi, Naoyuki Miyasaka   +6 more
doaj   +1 more source

The plasma D-dimer trends and their value in acute lower limb ischemia patients treated by catheter directed thrombolysis

Scientific Reports, 2021
To investigate the change trends of plasma D-dimer during catheter-directed thrombolysis (CDT) in acute lower limb ischemia (ALI) patients and their clinical value. A retrospective review of patients with ALI who received CDT was carried out.
Xiaochun Liu, Hailiang Xie, Guofu Zheng, Yuanfei Liu   +3 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Evaluation of treatment for diffuse large B-cell lymphoma using plasma D-dimer levels

Scientific Reports
It has been documented that D-dimer levels have potential utility as a measure of tumor activity in diffuse large B-cell lymphoma (DLBCL), however whether it can be used as a predictive marker of treatment outcome has not been established.
Ruonan Shao, Danchen Meng, Beibei Gao, Lu Zhang, Qingqi Meng, Yanqiu Hou, Zhangbiao Long, Jinsong Yan, Xiaofeng Shi   +8 more
doaj   +1 more source

Discrepant D-dimer results between Innovance D-Dimer and Vidas D-Dimer Exclusion II assays

Diagnostyka Laboratoryjna, 2015
Background. The concentration of D-dimer (DD) below the 500 ng/mL FEU cut-off value is one of the criteria for exclusion of venous thromboembolism (VTE). The aim of this study was to evaluate the incidence of increased plasma DD in patients with a low risk of VTE among healthy individuals and in patients who have had VTE episodes in the past. Material &
Tadeusz Góralczyk, Teresa Iwaniec, Jakub Siudut, Anetta Undas   +3 more
openaire   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Super Formula for Soluble C-Type Lectin-Like Receptor 2 × D-Dimer in Patients With Acute Cerebral Infarction

Clinical and Applied Thrombosis/Hemostasis
Acute cerebral infarction (ACI) includes atherosclerotic and cardiogenic ACI and involves a thrombotic state, requiring antithrombotic treatment. However, the thrombotic state in ACI cannot be evaluated using routine hemostatic examinations.
Toshitaka Kamon MD, Hideo Wada MD, PhD, Shotaro Horie MD, Tomoya Inaba MD, Karin Okamoto MD, Katsuya Shiraki MD, PhD, Yuhuko Ichikawa, Minoru Ezaki, Motomu Shimaoka MD, PhD, Akisato Nishigaki MD, Akihiro Shindo MD, PhD, Hideto Shimpo MD, PhD, Nobuo Ito MD   +12 more
doaj   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source